Agilent Technologies
Provides analytical instruments, diagnostics, consumables, software, and services for laboratory workflows.
Something off on this page? Send us feedback.
Profile
Sells chromatography and mass-spectrometry systems, pathology and genomics tools, laboratory software, consumables, services, and specialty pharmaceutical manufacturing to research, clinical, and industrial labs. Three segments span life sciences and diagnostics, vendor-neutral CrossLab support, and applied testing, linking instrument placements to ongoing service and consumables demand.
Supplies laboratory instruments, software, consumables, and services across three segments. Life Sciences and Diagnostics Markets combines liquid chromatography and mass spectrometry, cell analysis, pathology and companion diagnostics, genomics, and specialty pharmaceutical manufacturing. Agilent CrossLab provides vendor-neutral maintenance, columns and supplies, laboratory automation, and OpenLab informatics. Applied Markets centers on gas chromatography, spectroscopy, vacuum systems, and refurbished instruments for food, environmental, chemical, materials, and forensic testing.
Serves pharmaceutical and biotechnology companies, clinical laboratories, academia, government, and industrial testing customers across the Americas, Europe, and Asia Pacific. Breadth across instruments and vendor-neutral CrossLab support ties consumables, service, and software to installed laboratory workflows. Instrument demand depends on customer capital budgets; diagnostic products require regulatory approvals, and manufacturing and research sites span the United States, Europe, and Asia.
Company facts
Categories
Key statistics
Year to date +11.5% · Average volume (30d) 2.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 27, 2026 | Wells Fargo | Reiterate | Overweight | $160 | $180 | |
| Aug 27, 2026 | Barclays | Reiterate | Overweight | $140 | $175 | |
| Aug 27, 2026 | RBC Capital | Reiterate | Outperform | $180 | $185 | |
| Aug 27, 2026 | Evercore ISI | Reiterate | Outperform | $148 | $172 | |
| Aug 27, 2026 | Bernstein | Reiterate | Outperform | $180 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 26, 2026Q3 FY26 | $1.49 | $1.62 | +8.7% | $1.84B | $1.88B | +2.0% | +1.68% |
| May 27, 2026Q2 FY26 | $1.41 | $1.49 | +5.7% | $1.80B | $1.84B | +2.0% | +16.87% |
| Feb 25, 2026Q1 FY26 | $1.37 | $1.36 | −0.7% | $1.81B | $1.80B | −0.5% | −3.01% |
| Nov 24, 2025Q4 FY25 | $1.58 | $1.59 | +0.4% | $1.83B | $1.84B | +0.4% | +2.34% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.67B | $1.74B | $1.86B | $1.80B | $1.84B | $1.88B | |
| Gross profit | $866.0M | $914.0M | $964.0M | $946.0M | $1.01B | $0 | |
| Operating income | $300.0M | $360.0M | $443.0M | $353.0M | $399.0M | $444.0M | |
| Net income | $215.0M | $336.0M | $434.0M | $305.0M | $339.0M | $362.0M | |
| Diluted EPS | $0.75 | $1.18 | $1.53 | $1.07 | $1.20 | $1.28 | |
| Gross margin | 51.9% | 52.6% | 51.8% | 52.6% | 55.0% | 0.0% | |
| Operating margin | 18.0% | 20.7% | 23.8% | 19.6% | 21.7% | 23.6% |
Fiscal years (4-quarter sums)FY21 $6.32B · FY22 $6.85B · FY23 $6.83B · FY24 $6.51B · FY25 $6.95B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jul 31, 2026Cash & short-term investments $1.76B · Total debt $3.95B · Total assets $13.97B · Shareholders' equity $7.36B
Dividends
Raised for 13 straight years — most recently to $0.255 from $0.248 in Jan 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jun 30, 2026 | Jun 30 | Jul 22 | $0.255 | |
| Mar 31, 2026 | Mar 31 | Apr 22 | $0.255 | |
| Jan 6, 2026 | Jan 6 | Jan 28 | $0.255 | raised from $0.248 |
| Sep 30, 2025 | Sep 30 | Oct 22 | $0.248 | |
| Jul 1, 2025 | Jul 1 | Jul 23 | $0.248 | |
| Apr 1, 2025 | Apr 1 | Apr 23 | $0.248 | |
| Dec 31, 2024 | Dec 31 | Jan 22 | $0.248 | raised from $0.236 |
| Oct 1, 2024 | Oct 1 | Oct 23 | $0.236 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 282.43M · Float 281.47M · 99.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 25.60M | 9.06% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 18.45M | 6.53% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 14.44M | 5.11% | 13F | Aug 13, 2026 |
| State Street Corp | 12.85M | 4.55% | 13F | Aug 7, 2026 |
| Massachusetts Financial Services Co /MA/ | 10.01M | 3.54% | 13F | Aug 3, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 29, 2026 | Mikael Dolsten | director | −1,600 | $135.42 |
| Dec 1, 2025 | Mikael Dolsten | director | −2,600 | $149.81 |
| Nov 26, 2025 | Rodney Gonsalves | officer: V.P., Corporate Controller | −3,000 | $154.99 |
| Nov 18, 2025 | Padraig Mcdonnell | director, officer: President and CEO | −911 | $143.24 |
| Nov 12, 2025 | Padraig Mcdonnell | director, officer: President and CEO | −12,490 | $150.00 |
Peers
- Danaher
Broadest-overlap mega-peer: LC-MS, IHC pathology, and cell biology tools.
- Thermo Fisher Scientific
Dominant broad-platform rival in LC, MS, genomics, cell biology, and IHC.
- Waters
Most direct HPLC and LC-MS rival; ~40% global HPLC share; pharma QC-dominant.
- Bruker
Named 10-K rival in MS, NMR, and spectroscopy; expanding into spatial biology.
- Revvity
Multi-segment rival: analytical instruments, immunoassay, genomics, and imaging.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Waters | $414.33 | −0.03% | $31.02B | 103.4 | 26.5 | 6.7 | +113.3% |
| Bruker | $57.08 | +0.04% | $8.69B | — | 25.2 | 2.5 | +5.2% |
| Revvity | $127.20 | −1.25% | $14.37B | 61.3 | 22.9 | 4.9 | −1.3% |
| Median | 49.9 | 24.3 | 5.0 | +5.5% |